“The most important breakthrough in antidepressant treatment in decades.” – Dr. Thomas Insel, former Director, National Institute of Mental Health
Often called “phenomenal,” “tremendous,” “truly remarkable,” Intravenous Ketamine Therapy (IVKT) is rapidly gaining momentum and popularity throughout the medical and psychiatric communities. This therapy has been scientifically proven to provide relief where more traditional treatment modalities have failed. IVKT gives new hope to those who suffer from treatment-resistant mood disorders, PTSD, suicidal thoughts, and chronic pain.
In 60-75% of patients, Ketamine Infusion therapy can induce rapid and robust reduction of symptoms within minutes, and the benefits are often maintained for up to four (4) months. Ketamine is rarely associated with side effects or drug interactions. Currently there are no known contraindications for use with antidepressants, benzodiazepines, or other psychotropic medications.
INTRODUCTION TO KETAMINE INFUSION THERAPY
Treatment-resistant mood disorders and chronic pain are among the most painful experiences an individual can endure; in fact, each year, over a million people choose suicide rather than suffering another day with these conditions. Most people who live with these conditions have often been blamed for their conditions. Their symptoms have been referred to as “something you can control if you want to.” The general public wrongly assumes that these conditions are emotional in nature. However, those who suffer endure seriously debilitating physical symptoms. These symptoms may impede their ability to function normally. People with the worst cases often do not respond to traditional therapies. For them, depression, PTSD, Bipolar disorder, and chronic pain are often life – or death – sentences. Ketamine infusion therapy offers new hope.
For over 18 years researchers have known that small doses of ketamine can rapidly relieve depressive symptoms when delivered via slow intravenous infusion. The first scholarly paper describing this incredible discovery was published by Yale University in 2000. Since then, many more studies have been completed by Yale and other major institutions, including the National Institute of Mental Health, Harvard University, the Veterans Administration, Johns Hopkins, Mount Sinai Medical School, Oxford University, and many more. The original findings have by appointment only been confirmed over and over again.
Studies have focused on the worst cases: treatment-resistant patients who have suffered for years, for decades, often since childhood. They have been prescribed SSRIs, mood stabilizers, narcotics, and numerous other medications, psychological counseling, and other alternative therapies, with little or no success. An astonishing 70% of these extreme cases experience relief after their first low-dose Ketamine infusion.
If you are suffering, have given up hope for ever finding relief, Ketamine Infusion Therapy may be the answer you are looking for. Contact us for more information,
PET SCANS BY NIMH
PET Scans Revealed That Ketamine Rapidly Restored Bipolar Depressed Patients Ability To Anticipate Pleasurable Experiences By Boosting Activity In The Dorsal Anterior Cingulate Cortex (Yellow) And Related Circuitry. Picture Shows PET Scan Data Superimposed.
THE FUTURE IS HERE BY NIMH
The Rapid Action In Clinical Tests Of A Drug Called Ketamine, Which Lifted Depression In As Little As Two Hours In People With Treatment-Resistant Depression, Has Shown That It Is Possible To Develop Treatments That Work In Hours Instead Of Weeks.